Suplatast tosilate is under clinical development by Melius Pharma and currently in Phase II for Cough. According to GlobalData, Phase II drugs for Cough have a 41% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Suplatast tosilate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Suplatast tosilate overview
Suplatast tosilate is an an immunoregulatory compound. It is formulated as hard gelatin capsules and dry syrup for oral route of administration. It is under development for idiopathic pulmonary fibrosis (IPF) and cough related to IPF.
Suplatast tosilate was also under development for the treatment of interstitial cystitis.
Melius Pharma overview
Melius Pharma is a clinical-stage pharmaceutical company that develops treatments for severe diseases with unmet clinical needs at a development risk in fields of IPF, and chronic cough. The company is headquartered in Stockholm City, Stockholm, Sweden.
For a complete picture of Suplatast tosilate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
